Minerva Surgical

Minerva Surgical Net Margin

The Net Profit Margin of Minerva Surgical (UTRS) as of Nov 2, 2026 is -64.71 %. In the previous year, Net Profit Margin was -67.83 % — a change of -4.59% (higher).

Net Margin

-64.71 %

YoY

-4.59%

Last updated:

Net Profit Margin of Minerva Surgical is 2023 -64.71 % . Net Profit Margin of Minerva Surgical was 2022 -67.83 % . It decreases by -4.59% higher compared to the previous year.

For Minerva Surgical, the net margin of -70.7% is up versus -617.2% a few years ago.

The Minerva Surgical Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2019
-200.08 USD
Jan 1, 2020
-48.36 USD
Jan 1, 2021
-41.20 USD
Jan 1, 2022
-67.83 USD
Jan 1, 2023
-64.71 USD
The Minerva Surgical Net Margin history
YEARNet MarginYoY
-64.71 %-4.59%
-67.83 %+64.64%
-41.20 %-14.81%
-48.36 %-75.83%
-200.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Minerva Surgical Stock analysis

What does Minerva Surgical do? Minerva Surgical, Inc. generates revenue through the commercialization of minimally invasive uterine healthcare solutions designed to treat abnormal uterine bleeding without necessitating hysterectomies. The company offers a suite of products targeting structural and non-structural causes of AUB, which are utilized by OB/GYNs in hospitals, ambulatory surgical centers, and physician offices. These devices address drawbacks of alternative treatments while preserving the uterus, appealing to healthcare providers seeking effective, non-invasive options for women's health. The firm's product line includes commercially available devices for minimally invasive alternatives to hysterectomy, specifically targeting the most common causes of AUB across various uterine anatomies. OB/GYNs across multiple medical settings purchase these solutions, leveraging their ability to address treatment limitations while avoiding unnecessary surgical interventions. The company's focus on preserving the uterus through non-hysterectomy methods differentiates its offerings in the women's health technology market. Minerva Surgical's revenue model relies on sales of its medical devices to healthcare providers, particularly OB/GYNs, who integrate the products into their treatment protocols for patients with abnormal uterine bleeding. The company's solutions are positioned as alternatives to traditional hysterectomy procedures, targeting a significant unmet need in women's healthcare. This approach allows the firm to capture market share by addressing both clinical and patient preference demands for less invasive care options. Minerva Surgical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Minerva Surgical stock

Net Profit Margin of Minerva Surgical is -64.71 % in 2023.

Net Profit Margin of Minerva Surgical changed from -67.83 % to -64.71 %, representing a -4.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Minerva Surgical since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Minerva Surgical with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Minerva Surgical

All Key Metrics — Minerva Surgical